Clinical Trial Update: Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment

View source ↗

Summary

A clinical trial evaluating immune parameters in immune thrombocytopenia patients treated with eltrombopag has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Shandong University | Conditions: Immune Thrombocytopenia | Status: WITHDRAWN